BioSpace News Archive

Synthorx Inc. announced today the completion of a $63 million Series C financing.

BioLife Solutions, Inc. is a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media.

Data Reinforces Importance of Scar Prevention as an Important Goal of Acne Treatment

Forty Seven Inc. is a clinical-stage company focused on developing checkpoint therapies to activate macrophages in the fight against cancer

Genoptix will immediately begin Marketing, Selling and Distributing the complete Rosetta Genomics Portfolio

MyndYou (www.myndyou.com) today announced funding for a collaborative study with Genesis Rehab Services (GRS).

According to a report by Energias Market Research, the global medical cannabis market is anticipated to grow significantly from USD 8.28 billion in 2017 to USD 28.07 billion in 2024, at a CAGR of 19.1% from 2018 to 2024.

Stealth Biotherapeutics (Stealth), a clinical-stage biopharmaceutical company developing therapeutics to treat mitochondrial dysfunction, announced that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development has granted Orphan Drug Designation to Stealth’s investigational drug candidate, elamipretide, for the treatment of Leber’s hereditary optic neuropathy (LHON).

Acquisition accelerates Altum’s vision to build a premier, global women’s health company

LCS Group, LLC (“LCS”) announced today that it has filed a federal lawsuit in the Southern District of New York against Shire Plc, Shire Development LLC, and Shire LLC (“Shire”) alleging Shire breached its contract with LCS and interfered with LCS’s prospective economic advantage, as well as perpetrated fraud [active case number for the complaint is 1:18-cv-02688-AT].